Altamira Therapeutics Expands Distribution Agreement for Bentrio
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (NASDAQ: CYTO) has announced an extension of its exclusive distribution agreement with Pharma Nordic AS, now including Sweden and Denmark. This decision follows the successful launch of the Bentrio nasal spray in Norway, where the product has gained positive reception this year.
Bentrio's Role in Managing Allergic Rhinitis
Bentrio is a drug-free nasal spray specifically designed to prevent and treat allergic rhinitis. Its entry into the Swedish and Danish markets represents a significant advancement in offering effective treatment options for patients dealing with this condition. Pharma Nordic intends to apply its successful strategies from Norway to launch Bentrio in these two new regions next year.
Reasons for Market Expansion
Thomas Meyer, Chairman and CEO of Altamira Medica, expressed confidence in this partnership, stating, “We have been very pleased and impressed by Pharma Nordic’s market launch activities and success in Norway. It is therefore of mutual interest to expand the geographical scope of our collaboration.” This highlights the potential for Bentrio to become a significant player in allergic rhinitis management across Scandinavia.
Understanding Bentrio and Its Unique Formulation
Bentrio distinguishes itself as an over-the-counter nasal spray aimed at personal protection against airborne allergens. Its innovative formulation does not require drugs or preservatives, making it a safe treatment alternative for those seeking relief. When administered, Bentrio forms a protective gel layer in the nasal cavity, reducing exposure to airborne irritants and pathogens.
Clinical Trials and Effectiveness
Clinical trials have confirmed the effectiveness of Bentrio, particularly the NASAR study, which included 100 participants with seasonal allergic rhinitis. The results showed a statistically significant reduction in Total Nasal Symptom Scores (rTNSS), demonstrating the product's superior efficacy compared to saline nasal sprays. Participants reported significant improvements in their quality of life, underscoring Bentrio's potential to alleviate allergic symptoms.
About Altamira Therapeutics
Founded in 2003, Altamira Therapeutics is at the forefront of biomedical innovation. The company specializes in developing peptide-based nanoparticle technologies aimed at enhancing RNA delivery to extrahepatic tissues through its platforms OligoPhore™ and SemaPhore™. Currently, two flagship siRNA programs targeting KRAS-driven cancers and rheumatoid arthritis are in preclinical development, showcasing Altamira's dedication to advancing healthcare solutions.
Commercial Strategy and Future Aspirations
Additionally, Altamira holds a 49% stake in Altamira Medica AG, which manages the commercial distribution of Bentrio. The company is actively seeking partnerships to maximize the potential of its pipeline while exploring opportunities to divest from non-core legacy assets. This strategic approach will enable Altamira to concentrate on growth opportunities within the biopharmaceutical sector.
About Pharma Nordic
Pharma Nordic AS, based in Norway, possesses licenses for over-the-counter medicines and medical technical equipment throughout the Nordic regions. Its collaboration with Altamira reflects the company’s ambition to bring innovative healthcare products to market, ensuring that patients have access to effective therapeutic options.
Frequently Asked Questions
What is Bentrio used for?
Bentrio is an over-the-counter nasal spray intended for the prevention and treatment of allergic rhinitis, designed to protect against airborne allergens and viruses.
Who is distributing Bentrio in Scandinavia?
Pharma Nordic AS is the distributor for Bentrio in Scandinavia, having expanded their agreement with Altamira Therapeutics to include Sweden and Denmark.
What are the benefits of using Bentrio?
Bentrio is drug-free and preservative-free, providing a safe and effective alternative for individuals suffering from allergic rhinitis, as supported by clinical studies demonstrating its efficacy.
When is Bentrio expected to launch in Sweden and Denmark?
Pharma Nordic plans to introduce Bentrio to the Swedish and Danish markets next year, following its successful launch in Norway.
What are Altamira Therapeutics' main areas of focus?
Altamira Therapeutics is focused on developing nanoparticle technologies for RNA delivery and has ongoing projects targeting treatments for specific cancers and rheumatoid arthritis.
